A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity.
What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?
After watching this activity, participants should be better able to:
- Explain the testing methods used to identify patients with human epidermal growth factor receptor 2-positive (HER2+) colorectal cancer (CRC) and the interpretation of the results
- Summarize the current guidelines for managing patients with HER2+ CRC
- Discuss the recent efficacy and safety data for HER2-targeted agents in CRC
In this activity, three experts discuss the latest guidelines for identifying and treating patients with HER2+ CRC, as well as the efficacy and safety data for HER2-targeted agents and their impact on clinical practice. The discussion is guided by pre-canvassed questions provided by healthcare professionals involved in the management of patients with CRC.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of oncologists, pathologists and oncology nurses involved in the management of colorectal cancer.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Ian Chau discloses: Advisory board/panel fees from Astellas Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Incyte, Merck-Serono, MSD, OncXerna, Pierre Fabre, Roche, Seagen, Servier, Sotio, Taiho and Turning Point Therapeutics. Consultant for Bristol Myers Squibb, Eisai, Eli Lilly, Roche and Servier. Grants/research support from Eli Lilly and Janssen Cilag.
Dr Antonia Sepulveda discloses: Advisory board/panel fees from Merck (Relationship Terminated).
Dr Silvia Marsoni has no interests/relationships or affiliations to disclose in relation to this activity.
Bailey Blankenship, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Directors
Hannah Fisher, Sadaf Kazi and Christina Mackins-Crabtree have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.75 contact hours may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.
This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.
Date of original release: 13 December 2022. Date credits expire: 13 December 2024.
If you have any questions regarding credit please contact email@example.com.
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Takayuki Yoshino, ASCO 2022: PARADIGM trial of panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with MCRC
Optimizing the management of gastroenteropancreatic neuroendocrine tumoursThis activity is CE/CME accredited
Optimizing targeted therapy in colorectal cancer: How do the latest data impact clinical practice?This activity is CE/CME accredited
John L Marshall, ASCO 2018 – PARP inhibitors for the personalized treatment of colorectal cancer
Future of Radiotherapy Delivery in Rectal Cancer— European and US Approaches
Pancreatic Adenocarcinoma in the Older Adult
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 8 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!